First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL

Authors

John C. Byrd, The Ohio State University
Stephen Smith, University of Washington
Nina Wagner-Johnston, Washington University School of Medicine in St. Louis
Jeff Sharman, Willamette Valley Cancer Institute and Research Center
Andy I. Chen, Oregon Health & Science University
Ranjana Advani, Stanford School of Medicine
Bradley Auguston, Sir Charles Gairdner Hospital
Paula Marlton, Princess Alexandra Hospital
S. Renee Commerford, Genentech, Inc.
Kwame Okrah, Genetech, Inc.
Lichuan Liu, Genentech, Inc.
Elaine Murray, Genentech, Inc.
Elicia Penuel, Genentech, Inc.
Ashley F. Ward, Genentech, Inc.
Ian W. Flinn, Sarah Cannon Research Institute

Journal

Oncotarget

Publication Date

2018

Volume

9

Issue

16

Inclusive Pages

13023-13035

Document Type

Open Access Publication

Rights and Permissions

Byrd, J. C., Smith, S., Wagner-Johnston, N., Sharman, J., Chen, A. I., Advani, R., . . . Flinn, I. W. (2018). First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget, 9(16), 13023-13035. 10.18632/oncotarget.24310. Copyright: Byrd et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Recommended Citation

Byrd, John C.; Smith, Stephen; Wagner-Johnston, Nina; Sharman, Jeff; Chen, Andy I.; Advani, Ranjana; Auguston, Bradley; Marlton, Paula; Commerford, S. Renee; Okrah, Kwame; Liu, Lichuan; Murray, Elaine; Penuel, Elicia; Ward, Ashley F.; and Flinn, Ian W., "First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL." Oncotarget. 9, 16. 13023-13035. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/6653